New Drug Development

Our Resources

The COG Phase 1 & Pilot Consortium successfully leverages the database infrastructure and resources of the parent Children’s Oncology Group (COG) while maintaining its own administrative and operational infrastructure to ensure rapid development, implementation and reporting of specialized and complex early phase clinical trials.

The Consortium has expert resources for the conduct of translational biology, pharmacokinetic, and pharmacogenetics studies, and has developed a state-of-the art infrastructure to facilitate image transfer of specialized correlative imaging studies for central review and analyses.

Industry Partners

Our experienced investigators have in-depth experience in the design and conduct of early phase cancer trials in children, with the ability to deliver data to support regulatory submissions in a time and cost effective manner.

The COG drug development experience extends into phase 2 trials. Given how rare childhood cancers are, the COG network is a proven mechanism to accrue eligible subjects to clinical trials of promising new therapies. COG offers the ability to leverage an existing remote data entry system, or to work directly with industry sponsors or CROs. The COG has a proven track record of delivering results that matter.

NCTN_h_COLOR_Badge_180x60.png

 

 

 

   amazon smile donate